Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data

At present, for the treatment of second line advanced nonsmall cell lung cancer (NSCLC), three drugs are now available, pemetrexed, docetaxel and erlotinib (1-3). Docetaxel was registered in a superiority trial over placebo and it became the first second line approved at the beginning of this century, while erlotinib was licensed with a pivotal trial against placebo five years later (2).